Tissue-specific regulation of protein synthesis by insulin and free fatty acids.
The purpose of the study described herein was to investigate how the mammalian target of rapamycin (mTOR)-signaling pathway and eukaryotic initiation factor 2B (eIF2B) activity, both having key roles in the translational control of protein synthesis in skeletal muscle, are regulated in cardiac muscle of rats in response to two different models of altered free fatty acid (FFA) and insulin availability. Protein synthetic rates were reduced in both gastrocnemius and heart of 3-day diabetic rats. The reduction was associated with diminished mTOR-mediated signaling and eIF2B activity in the gastrocnemius but only with diminished mTOR signaling in the heart. In response to the combination of acute hypoinsulinemia and hypolipidemia induced by administration of niacin, protein synthetic rates were also diminished in both gastrocnemius and heart. The niacin-induced changes were associated with diminished mTOR signaling and eIF2B activity in the heart but only with decreased mTOR signaling in the gastrocnemius. In the heart, mTOR signaling and eIF2B activity correlated with cellular energy status and/or redox potential. Thus FFAs may contribute to the translational control of protein synthesis in the heart but not in the gastrocnemius. In contrast, insulin, but not FFAs, is required for the maintenance of protein synthesis in the gastrocnemius.
Crozier
Stephen J
SJ
Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Anthony
Joshua C
JC
Schworer
Charles M
CM
Reiter
Ali K
AK
Anthony
Tracy G
TG
Kimball
Scot R
SR
Jefferson
Leonard S
LS
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000378:metabolism; D020717:Eukaryotic Initiation Factor-2B / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D006321:Heart / Q000187:drug effects; D007328:Insulin / Q000378:metabolism*; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D009525:Niacin / Q000494:pharmacology; D009928:Organ Specificity; D014176:Protein Biosynthesis; D011499:Protein Processing, Post-Translational; D051381:Rats; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000378:metabolism*
D020717:Eukaryotic Initiation Factor-2B; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D009525:Niacin; D020123:Sirolimus